




2023

Histamine H3 receptor antagonism mitigates food-hypersensitivity-associated depressive behavior and neuropathology in a mouse model of cow's milk allergy

Danielle Germundson-Hermanson
University of North Dakota

[How does access to this work benefit you? Let us know!](#)

Follow this and additional works at: <https://commons.und.edu/bms-pp>

 Part of the [Allergy and Immunology Commons](#), [Biological Phenomena, Cell Phenomena, and Immunity Commons](#), and the [Pathology Commons](#)

Recommended Citation

Germundson-Hermanson, Danielle, "Histamine H3 receptor antagonism mitigates food-hypersensitivity-associated depressive behavior and neuropathology in a mouse model of cow's milk allergy" (2023). *Biomedical Sciences Posters and Presentations*. 4.
<https://commons.und.edu/bms-pp/4>

This Poster is brought to you for free and open access by the Department of Biomedical Sciences at UND Scholarly Commons. It has been accepted for inclusion in Biomedical Sciences Posters and Presentations by an authorized administrator of UND Scholarly Commons. For more information, please contact und.common@library.und.edu.

Histamine H3 receptor antagonism mitigates food-hypersensitivity-associated depressive behavior and neuropathology in a mouse model of cow's milk allergy

Danielle Germundson-Hermanson¹ and Kumi Nagamoto-Combs²
Departments of ¹Pathology and ²Biomedical Sciences, University of North Dakota SMHS



Introduction

Background

Histamine is best known for causing allergy symptoms, but it also regulates blood-brain barrier permeability¹ and oligodendrocyte differentiation². Thus, brain histamine levels are tightly controlled.

Previous Findings

We demonstrated that histamine and histamine H3 receptor (H3R) levels were elevated in a mouse model of cow's milk allergy (CMA) in association with intracranial mast cell activation, depression-like behaviors, and cortical demyelination^{3,4}

Gaps in Knowledge

In humans, food allergies are often associated with neuropsychiatric disorders⁵⁻⁷, but the involvement of allergy-induced histamine in triggering behavioral changes is unclear.

Hypothesis

Repeated allergen consumption can lead to central histaminergic dysfunction through H3R, ultimately resulting in cortical demyelination and aberrant behaviors.

Study Objectives

We aimed to elucidate if antagonizing H3R could improve the behavioral and neuropathological outcomes in our mouse model after induction of CMA with repeated dietary allergen exposure.

Methods

Animals and Treatments

Four-week-old male C57BL/6J mice (n=17-20) were purchased from Jackson Laboratories and underwent sham or CMA sensitization once a week for 5 weeks as shown in Fig 1. Both sham and CMA-sensitized treatment groups were then placed on a diet containing 0.3% whey proteins for two weeks with 30 mg/kg of the H3R antagonist thioperamide (thio) or saline (vehicle) given daily by oral gavage. During Week 7, mice were subjected to a series of behavioral tests and then euthanized via CO₂ asphyxiation. All animal use was approved by UND IACUC.




Fig 1. Experimental timeline

Enzyme-Linked Immunosorbent Assays (ELISAs)

The allergen-specific IgE ELISA was performed as described previously⁸ with 5 µL of plasma. The competitive histamine ELISA was carried out according to the manufacturer's instructions using 10 µL of plasma.

Immunofluorescence Staining

Whole mount dura underwent antigen retrieval in a tris EDTA buffer (pH 9) with 0.2% tween-20 overnight at 37 °C. Dura and 40-µm brain sections were blocked in PBS containing 0.5% BSA, 0.5% NGS, and 0.1% Triton-X 100 and incubated in a primary antibody against IgE (1:200) and CD117 (1:200) or neurofilament heavy chain (1:3000) at 4 °C overnight, respectively. Antigens were visualized using fluorescently conjugated secondary antibodies and/or dyed with FluoroMyelin™ Red. All tissues were coverslipped with mounting media containing DAPI counterstain.

Statistical Analysis

Results were compared using GraphPad Prism v9.5.1 software. Statistical tests used are indicated in figure legends. A $p < 0.05$ was considered significant.

Results






Fig 2. Thioperamide did not affect the sensitization-induced allergen-specific IgE or histamine levels of CMA mice. Terminal plasma collected at the end of Week 7 confirmed that daily treatment with thioperamide did not significantly influence the hypersensitivity to the whey-containing diet (Multiple Mann-Whitney tests and 2-way ANOVA; Mean ± SEM; Outliers were removed by the ROUT method (Q=1%) from the histamine ELISA).

Tail Suspension Test



Novel Object Recognition





Fig 3. Thioperamide treatment prevented depression-like behavior and memory impairment in CMA mice. During Week 7 mice were subjected to the tail suspension test and novel object recognition to measure their depression-like behavior and recognition memory, respectively. Vehicle-treated CMA mice had significantly increased immobile time and a decreased memory index compared to sham mice. Thioperamide-treated mice had no significant behavioral or memory changes when tested. (Multiple Mann-Whitney tests and 2-way ANOVA; Mean ± SEM; Outliers were removed by the ROUT method (Q=1%) from behavioral testing).




Fig 4. Thioperamide did not change IgE-sensitization or activation of intracranial mast cells. CD117-immunopositive mast cells were abundant throughout the dura of all groups. However, when the number of mast cells per 20 high-powered fields were counted, there was an increase in the number of degranulated (open bars) but not granulated (closed bars) in CMA mice compared to sham mice. Furthermore, in CMA mice, most degranulated mast cells were IgE-immunopositive. Photomicrographs were taken using a 100X objective. (a indicates significance of the total mast cells between groups and b indicates significance of only degranulated mast cells between groups; Multiple Mann-Whitney tests and 2-way ANOVA; Mean ± SEM).




Fig 5. Thioperamide treatment ameliorated CMA-associated demyelination. Brain tissue was immunostained with neurofilament-heavy (NF-H) for neuronal cell bodies and axons, dyed with FluoroMyelin™ (FM) for the myelin sheath. Cortical demyelination was apparent after repeated allergen exposure in saline-treated BLG mice. Diminished NF-H immunofluorescence was also observed in the cortex of this group. BLG-sensitized mice given thioperamide did not have a notable decrease in myelin or NF-H staining. Photomicrographs were taken from the anterior cingulate and primary motor cortex using a 10X objective.

Discussion

- Thioperamide effectively prevented allergy-associated depression-like behavior and cognitive impairment without altering the hypersensitivity status of the CMA mice or intracranial mast cell activation, signifying the involvement of H3R in food allergy-triggered neuropsychiatric disorders.
- Thioperamide treatment also appeared to prevent changes in food allergy-associated cortical demyelination.
- We have previously observed cortical demyelination after CMA sensitization³. The loss of myelin seemed to have also affected the axonal structure suggested by the decreased NF-H immunoreactivity in the cortex of vehicle-treated CMA mice, although further confirmation is needed.
- Histamine signaling through H3R has been demonstrated to decrease oligodendrocyte differentiation and myelination². Additional investigation is needed to confirm the role of altered oligodendrocyte functions in the progression of cortical demyelination in our mouse model.




Fig 6. Working hypothesis

Conclusion

Our findings strongly suggest that that excessive signaling through H3R is involved in the development of food allergy-associated neuropsychiatric disorders and neuropathology. Therapeutics targeting histamine production or signaling may be a strategy to reduce the risk of demyelinating and neurodegenerative disorders in some susceptible individuals.

References

- Wallin MT et al (2019) *Neurology*. 93(15):688.
- Chen Y et al (2017) *PLoS One*. 12(12):e0189380
- Germundson DL and Nagamoto-Combs K (2022) *Cells*. 11(4):738
- Germundson DL et al (2020) *Brain Res*. 1749:147148
- Shanahan L et al (2014) *J Psysom Res*. 77(6): 468-473.
- Costa-Pinto FA and Basso AS (2012) *Chem Immunol and Allergy*. 98:222-39.
- Topal E et al (2016) *Allergol Immunopathol* 44(5):445-9.
- Germundson DL and Nagamoto-Combs K (2021) *Mol Bio*. 223:159-67

Acknowledgements

Funding provided by NIH grants 1R01AI168563-01, P20GM113123-06, and P20GM103442. Illustrated icons were created using BioRender.com